BIX0 Stock Chart & Stats
€1.95
-€0.04(-1.81%)
At close: 4:00 PM EDT
€1.95
-€0.04(-1.81%)
Day’s Range― - ―
52-Week Range€1.90 - €3.55
Previous CloseN/A
Volume0.00
Average Volume (3M)167.00
Market Cap
€139.47M
Enterprise Value€1.01K
Total Cash (Recent Filing)€456.48M
Total Debt (Recent Filing)€6.25M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 27, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding65,804,360
10 Day Avg. Volume0
30 Day Avg. Volume167
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.14Price Target Upside317.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€15.10M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Financial FlexibilityVery low debt (≈2% of equity) is a durable structural strength: it reduces refinancing and interest-rate risk and preserves capacity to raise capital or absorb development setbacks. This flexibility supports multi-quarter R&D investment and partnership activity without heavy fixed-charge constraints.
Proprietary Discovery PlatformsOwning proprietary antibody discovery and validation platforms is a long-lived competitive asset. It enables repeatable candidate generation, increases partner leverage in deals, and underpins recurring collaboration/licensing revenue potential, supporting sustainable pipeline replenishment and partner interest.
High Gross Margins On RevenueNear-100% gross profit implies the company's revenue streams (licenses, milestones, royalties) are highly scalable and not tied to heavy COGS. Structurally, this means additional revenue from partnerships or future sales could flow to operating profit more directly, enhancing operational leverage as top line grows.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow of roughly -260M TTM is a structural weakness: it forces repeated external funding, increases dilution risk, and constrains the firm's ability to advance multiple programs simultaneously. Over months this limits strategic optionality and increases financing dependence.
Deep Operating LossesOperating and net losses materially exceed revenue (~1.5x TTM), indicating the cost base is structurally misaligned with current income. This persistent unprofitability depresses returns on equity, necessitates frequent capital raises or partner dealmaking, and lengthens the timeline to self-sustaining operations.
Revenue Volatility And Recent DeclineRevenue is lumpy and fell -3.8% TTM after prior gains, reflecting milestone-driven and partnership timing. This structural volatility makes cash flow forecasting and steady investment planning difficult, increasing execution risk for clinical programs and reliance on the timing of external partner payments.
BioInvent International AB News
BIX0 FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was €1.90 and its highest was €3.54 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is €139.47M.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Aug 27, 2026 which is in 29 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Apr 29, 2026. The company reported -€0.172 earnings per share for the quarter, the consensus estimate of -€0.172 by €0.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Undervalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -0.17.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -€0.172 in its last earnings report, expectations of -€0.172. Following the earnings report the stock price went up 0.5%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in DE:BIX0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
BIX0 Stock 12 Month Forecast
Average Price Target
€8.14
▲(317.44% Upside)
Technical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―